The Dr. Martens Board has declared a final dividend of 1.70p, taking the total dividend for FY25, including the interim dividend of 0.85p, to 2.55p (FY24: 2.55p). This will be paid to shareholders on the register as at 29 August 2025 with payment on 8 October 2025.
Other financial highlights include:
Delivered on all four objectives set at the start of the year:
1. Americas direct-to-consumer channel ("DTC") back into growth in H2
2. Marketing approach reset to relentlessly focus on product
3. £25m of annualised cost savings delivered - the top end of guidance
4. Balance sheet significantly strengthened ahead of target
Group revenue of £787.6m, down 8% CC and 10% reported, in line with guidance (FY24: £877.1m) against a challenging macroeconomic and consumer backdrop in several of our core markets
Adjusted PBT of £34.1m or £40.3m CC (FY24: £97.2m)
Reported PBT (post exceptionals and adjusting items) of £8.8m (FY24: £93.0m)
Strong cash generation, driven by inventory reduction, leading to significant decrease in net debt to £94.1m excluding lease liabilities (FY24: £177.5m), or £249.5m including leases (FY24: £359.8m)
Refinance completed successfully, securing a new £250.0m term loan together with a £126.5m RCF
